From: Sona Nanotech Inc.
Date: April 7, 2026
Sona Nanotech Inc. (CSE: SONA, OTCQB: SNANF) (the “Company”, “Sona”) is excited to announce publication of a preclinical study using its Targeted Hyperthermia Therapy (“THT”) to treat cancer, in the Journal of Nanobiotechnology which demonstrated treatment durability to the end of the 45 day study period when it was given in combination with immunotherapy.
Building on its prior body of preclinical research treating melanoma and breast cancer (as published in Frontiers in Immunology), this study was conducted in an immunologically ‘cold’ colorectal cancer (CT26) tumor model. In this combination protocol, CT26 tumor-bearing animals were treated with two consecutive treatments of THT plus standard PD-1 inhibitor immunotherapy followed by three additional PD-1 treatments (the “Study”). Animals were followed for 45 days following initiation of treatment as per study protocol. At completion of the Study 38% of animals given the combined therapy were alive and disease free.